Experimental mRNA Vaccine Shows 42 Percent Reduction in Melanoma Recurrence and Death in Landmark Phase 3 Trial
A significant advancement in oncology has emerged as pharmaceutical giants Merck and Moderna released the definitive results of their Phase 3 clinical trial for a personalized mRNA-based cancer vaccine. The…
